According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
A number of other research analysts have also weighed in on NEOS. Cantor Fitzgerald reissued a buy rating and issued a $20.00 price objective on shares of Neos Therapeutics in a report on Wednesday, March 27th. ValuEngine lowered Neos Therapeutics from a hold rating to a sell rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $9.69.
Neos Therapeutics stock traded down $0.01 during midday trading on Thursday, reaching $2.35. The company’s stock had a trading volume of 81,896 shares, compared to its average volume of 350,174. The company has a debt-to-equity ratio of 5.51, a quick ratio of 1.37 and a current ratio of 1.55. Neos Therapeutics has a 52-week low of $1.40 and a 52-week high of $8.44. The stock has a market cap of $116.85 million, a PE ratio of -1.47 and a beta of 0.95.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The business had revenue of $15.39 million during the quarter, compared to analysts’ expectations of $18.90 million. As a group, sell-side analysts predict that Neos Therapeutics will post -0.66 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in the company. Nantahala Capital Management LLC acquired a new stake in Neos Therapeutics during the fourth quarter worth about $7,400,000. Stonepine Capital Management LLC lifted its position in Neos Therapeutics by 1,747.2% during the fourth quarter. Stonepine Capital Management LLC now owns 4,210,153 shares of the company’s stock worth $6,947,000 after buying an additional 3,982,234 shares in the last quarter. Broadfin Capital LLC purchased a new position in Neos Therapeutics during the fourth quarter worth approximately $4,321,000. Sphera Funds Management LTD. lifted its position in Neos Therapeutics by 164.7% during the fourth quarter. Sphera Funds Management LTD. now owns 2,201,697 shares of the company’s stock worth $3,633,000 after buying an additional 1,370,000 shares in the last quarter. Finally, BlackRock Inc. lifted its position in Neos Therapeutics by 28.8% during the fourth quarter. BlackRock Inc. now owns 2,733,411 shares of the company’s stock worth $4,510,000 after buying an additional 610,660 shares in the last quarter. 50.97% of the stock is currently owned by institutional investors and hedge funds.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
See Also: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.